Childhood Absence Epilepsy Treatment Market - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Childhood Absence Epilepsy Treatment Market - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Childhood absence epilepsy diagnosis revolves around identifying symptoms and categorizing the epilepsy type based on those symptoms. Diagnostic methods and techniques for childhood absence epilepsy include electroencephalogram (EEG)/video telemetry, magnetic resonance imaging (MRI scans), and blood tests. In electroencephalogram (EEG)/video telemetry, electrical signals from brain are recorded in a computer by asking the patient to hyperventilate for 3 to 5 minutes, which triggers an absence seizure. The EEG then shows spikes and wave discharges at 3 Hz (cycles per second) that are generalized in nature (similar on both sides of the brain). Structural causes behind epilepsy can be understood with the help of MRI scans (as some patients suffering from epilepsy due to brain damage can be found by a MRI scan). Blood tests may be required to diagnose any medical conditions, which may be the reason behind epilepsy.
Market Dynamics
Key players in the market are focused on the development of new drugs for the treatment of childhood absence epilepsy. Factors such as increasing prevalence of the disease, increasing accessibility of medications, and presence of drugs in pipeline for childhood absence epilepsy treatment (Insys therapeutics and Cavion, Inc.) are expected to boost the global childhood absence epilepsy treatment market growth. Product launches by generic manufacturers in the U.S. as well as globally is expected to support growth of the market. For instance, Dr. Reddy’s Laboratories launched generic lamotrigine orally disintegrating tablets in the U.S. in 2021. Moreover, a number of manufacturers such as Insys Therapeutics (Cannabidiol) and Cavion, Inc. (CX-8998) have drugs in phase II stage in clinical trials and these therapies are expected to be launched over the forecast period.
Key features of the study:
This report provides in-depth analysis of childhood absence epilepsy treatment market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
It profiles leading players in the global childhood absence epilepsy treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies
Key companies covered as a part of this study include Cavion, Inc., Pfizer, Inc., GlaxoSmithKline Plc, Insys Therapeutics, Inc., AbbVie, Inc., and Teva Pharmaceutical Industries Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, by technology up-gradation, market expansion, and marketing tactics
The global childhood absence epilepsy treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision making through various strategy matrices used in analyzing the childhood absence epilepsy treatment market
Detailed Segmentation:
Global Childhood Absence Epilepsy Treatment Market, By Drug:
Ethosuximide
Valproate
Lamotrigine
Phase 2 Drugs
Cannabidiol Oral Solution
CX-8998
Global Childhood Absence Epilepsy Treatment Market, By Disease Type:
Typical Absence Seizures
Atypical Absence Seizures
Global Childhood Absence Epilepsy Treatment Market, By Region:
North America
By Drug
Ethosuximide
Valproate
Lamotrigine
Phase 2 Drugs
Cannabidiol Oral Solution
CX-8998
By Disease Type:
Typical Absence Seizures
Atypical Absence Seizures
By Country:
U.S.
Canada
Europe
By Drug
Ethosuximide
Valproate
Lamotrigine
Phase 2 Drugs
Cannabidiol Oral Solution
CX-8998
By Disease Type:
Typical Absence Seizures
Atypical Absence Seizures
By Country:
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
By Drug
Ethosuximide
Valproate
Lamotrigine
Phase 2 Drugs
Cannabidiol Oral Solution
CX-8998
By Disease Type:
Typical Absence Seizures
Atypical Absence Seizures
By Country:
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
By Drug
Ethosuximide
Valproate
Lamotrigine
Phase 2 Drugs
Cannabidiol Oral Solution
CX-8998
By Disease Type:
Typical Absence Seizures
Atypical Absence Seizures
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Middle East
By Drug
Ethosuximide
Valproate
Lamotrigine
Phase 2 Drugs
Cannabidiol Oral Solution
CX-8998
By Disease Type:
Typical Absence Seizures
Atypical Absence Seizures
By Country:
GCC
Israel
Rest of Middle East
Africa
By Drug
Ethosuximide
Valproate
Lamotrigine
Phase 2 Drugs
Cannabidiol Oral Solution
CX-8998
By Disease Type:
Typical Absence Seizures
Atypical Absence Seizures
By Country:
Central Africa
South Africa
North Africa
Company Profiles
Cavion, Inc. *
Company Overview
Product Portfolio
Financial Performance
Key Strategies
Recent Developments
Pfizer, Inc.
GlaxoSmithKline Plc
Insys Therapeutics, Inc.
AbbVie, Inc.
Teva Pharmaceutical Industries Ltd.

“*” marked represents similar segmentation in other categories in the respective section.